Journal
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 92, Issue 2, Pages 577-582Publisher
ENDOCRINE SOC
DOI: 10.1210/jc.2006-0369
Keywords
-
Categories
Funding
- NCCIH NIH HHS [P50 AT000477, P50 AT00477, P50 AT000477-070001] Funding Source: Medline
- NCRR NIH HHS [M01-RR-750] Funding Source: Medline
Ask authors/readers for more resources
Introduction: The purpose of this 3-way crossover study was to identify the effective dose of soy protein isolate enriched with isoflavones for suppressing bone resorption in postmenopausal women using a novel, rapid assessment of antibone resorbing treatments. Methods: Thirteen postmenopausal women (>= 6 yr since menopause) were predosed with Ca-41 iv. After a 200-d baseline period, subjects were given 43 g soy protein/d that contained 0, 97.5, or 135.5 mg total isoflavones in randomized order. The soy protein isolate powder was incorporated into baked products and beverages. Each 50-d intervention phase was preceded by a 50-d pretreatment phase for comparison. Serum isoflavone levels and biochemical markers were measured at the end of each phase. Twenty-four-hour urine samples were collected approximately every 10 d during each phase for Ca-41/Ca analysis by accelerator mass spectrometry. Results: Serum isoflavone levels reflected the amount of isoflavones consumed in a dose-dependent manner. None of the isoflavone levels had a significant effect on biochemical markers of bone turnover, urinary cross-linked N teleopeptides of type I collagen and serum osteocalcin, or bone turnover as assessed by urinary Ca-41/Ca ratios. Conclusions: Soy protein with isoflavone doses of up to 135.5 mg/d did not suppress bone resorption in postmenopausal women. This is the first efficacy trial using the novel technique of urinary Ca-41 excretion from prelabeled bone.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available